High expression of GRB2 associated binding protein 3 mRNA predicts positive prognosis in melanoma. Issue 1 (20th December 2022)

• Record Type: Journal Article
• Authors: Li, Chunting; Ye, Zhenzhen; Wang, Yimeng; Wang, Guanyu; Zhang, Qian; Zhang, Chunlei
• Is Part Of: Melanoma research. Volume 33:Issue 1(2023)
• Page Start: 27
• Page End: 37
• Publication Date: 2022-12-20
• Subjects: GAB3 -- macrophages -- melanoma -- natural killer cells; Melanoma -- Periodicals; Melanoma -- Periodicals; Melanomen; 616.99477
• DOI: 10.1097/CMR.0000000000000861
• Languages: English
• ISSNs: 0960-8931

Abstract

Abstract : Malignant melanoma is the most aggressive form of skin cancer, and it is characterized by poor prognosis in patients with metastatic diseases. Accurate prediction of prognosis is crucial for therapeutic decisions. In this study, bioinformatics analysis was used to explore the prognostic value of growth factor receptor-bound protein 2-associated binding protein 3 ( GAB 3) mRNA. RNA transcriptome sequencing data and clinical data from The Cancer Genome Atlas and genotype-tissue expression (GTEx) were analyzed for differentially expressed genes in high and low GAB3 mRNA expression groups in melanoma. Performing gene enrichment analysis and constructing protein–protein interaction networks. High expression of G AB 3 was significantly correlated with a lower T stage, melanoma Clark level, Breslow depth, and melanoma ulceration. And high GAB 3 expression was also associated with better progression-free interval in T1 and T2 stages and N0 stage and longer overall survival in T1 and T2 stages, N0 stage, and N1 stage. GAB3 promoted high levels of infiltration of macrophages and activated natural killer cells in melanoma. High expression of GAB3 predicted a positive prognosis in early-stage melanoma that may be mediated by the anticancer immune response.